Gary Ansel, MD, Discusses Unanswered Questions in Trials of Drug-Eluting Stents

Submitted on Wed, 11/30/2016 - 15:29
Multimedia Type
Text Below

At the 43rd VEITHsymposium, Dr. Ansel presented data from the randomized controlled trial studying the Zilver PTX drug-eluting stent (DES) vs percutaneous transluminal angioplasty and bare-metal stents. He shared new findings from subanalyses as well as 5-year results that show widening benefits from the DES. Vascular Disease Management spoke with Dr. Ansel at the meeting about these results and the future of DES.